Ventana to Develop CDx for Genmab Cancer Drug | GenomeWeb

NEW YORK (GenomeWeb News) – Roche business Ventana today announced a companion diagnostic development deal for a Genmab antibody drug conjugate program.

Ventana will develop an immunohistochemistry CDx test for detecting tissue factor in patient tumor samples with the intent that the assay could be used as the screening test in clinical trials for Genmab's HuMax-TF-ADC, Ventana said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.